Marcelo Almeida Nakashima

Marcelo Almeida Nakashima

Auto-generated profile, based on publicly available information

Marcelo Almeida Nakashima

Department of Pharmacology, Universidade Federal de Santa Catarina, Florianopolis, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Journal of the American Society of Hypertension
Verified
Journal Article
Closed access
JSJanaina A. Simplicio
Janaina A. Simplicio
NGNatália A. Gonzaga
Natália A. Gonzaga
MNMarcelo A. Nakashima
Marcelo A. Nakashima
BMBruno S. De Martinis
Bruno S. De Martinis
TCThiago M. Cunha
Thiago M. Cunha
Carlos R. TirapelliCarlos R. Tirapelli
Carlos R. Tirapelli

1 September 2019 in Cytokine
Verified
Journal Article
Closed access
MNMarcelo A. Nakashima
Marcelo A. Nakashima
CSCarla B.P. Silva
Carla B.P. Silva
NGNatalia A. Gonzaga
Natalia A. Gonzaga
JSJanaina A. Simplicio
Janaina A. Simplicio
AOAna C.M. Omoto
Ana C.M. Omoto
Carlos R. TirapelliCarlos R. Tirapelli
Carlos R. Tirapelli

28 February 2025 in Acute and Critical Care
Verified
Journal Article
Open access
MNMarcelo Almeida Nakashima
Marcelo Almeida Nakashima
GDGabrielle Delfrate
Gabrielle Delfrate
LALucas Braga Albino
Lucas Braga Albino
GAGustavo Ferreira Alves
Gustavo Ferreira Alves
JOJunior Garcia Oliveira
Junior Garcia Oliveira
DFDaniel Fernandes
Daniel Fernandes
Background: Sepsis is a life-threatening condition that affects the cardiovascular and renal systems. Severe hypotension during sepsis compromises tissue perfusion, which can lead to multiple organ dysfunction and death. Phosphodiesterase 5 (PDE5) degrades intracellular cyclic guanosine monophosphate (cGMP) levels which promotes vasodilatation in specific sites. Our previous studies show that inhibiting cGMP production in early sepsis increases mortality, implying a protective role for cGMP production. Then, we hypothesized that cGMP increased by tadalafil (PDE5 inhibitor) could improve microcirculation and prevent sepsis-induced organ dysfunction.Methods: Rats were submitted to cecal ligation and puncture (CLP) sepsis model and treated with tadalafil (2 mg/kg, s.c.) 8 hours after the procedure. Hemodynamic, inflammatory and biochemical assessments were performed 24 hours after sepsis induction. Moreover, the effect of tadalafil on the survival of septic rats was evaluated for 5 days.Results: Tadalafil treatment improves basal renal blood flow during sepsis and preserves it during noradrenaline infusion. Sepsis induces hypotension, impaired response to noradrenaline, and increased cardiac and renal neutrophil infiltration, in addition to increased levels of plasma nitric oxide and lactate. None of these dysfunctions were changed by tadalafil. Additionally, tadalafil treatment did not increase the survival rate of septic rats.Conclusions: Tadalafil improved microcirculation of septic animals; however, no beneficial effects were observed on macrocirculation and inflammation parameters. Then, the potential benefit of tadalafil in the prognosis of sepsis should be evaluated within a therapeutic strategy covering all sepsis injury mechanisms.